The efficacy and safety of sequential use of anlotinib and 131I for locally advanced or metastatic differentiated thyroid cancer: A single-arm phase II clinical trial

被引：0
|
作者：
Song, Hongjun
Qiu, Xian
He, Ziyan
Chen, Libo
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 6, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Peoples Hosp 6, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18102
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial
    Zhu, Jun
    Song, Chunyan
    Zheng, Zhong
    Xia, Lingfang
    Chen, Yanqiong
    Ke, Guihao
    Wu, Xiaohua
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [32] Sintilimab plus anlotinib in patients with advanced sarcomas (SINANLOSARC): A single-centre, single-arm, phase II trial
    Liu, Z.
    Liu, M.
    Xu, J.
    Fu, H.
    Zhu, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S1038 - S1038
  • [33] A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer
    Ji, Dongmei
    Song, Lijie
    Cheng, Ying
    Shen, Weina
    Kuang, Muyu
    Chen, Jiaying
    Yang, Minjie
    Cui, Hongxia
    Zhou, Jinghong
    Shi, Haiyan
    Tan, Panfeng
    Fan, Songhua
    Shi, Michael
    Su, Weiguo
    Ji, Qinghai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer
    Del Rivero, Jaydira
    Edgerly, Maureen
    Ward, Jean
    Madan, Ravi A.
    Balasubramaniam, Sanjeeve
    Fojo, Tito
    Gramza, Ann W.
    ONCOLOGIST, 2019, 24 (01): : 16 - +
  • [35] Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial
    Tian, Zhichao
    Dong, Shuping
    Zuo, Wenli
    Li, Po
    Zhang, Fan
    Gao, Shilei
    Yang, Yonghao
    Li, Chao
    Zhang, Peng
    Wang, Xin
    Wang, Jiaqiang
    Yao, Weitao
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [36] First line anlotinib plus liposomal doxorubicin for locally advanced or metastatic soft tissue sarcoma: A prospective, single-arm trial
    Sun, Xin
    Zhang, Ranxin
    Xu, Jie
    Xie, Lu
    Guo, Wei
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2022, 15 (06) : 266 - 273
  • [37] First line anlotinib plus liposomal doxorubicin for locally advanced or metastatic soft tissue sarcoma: A prospective, single-arm trial
    Xin Sun
    Ranxin Zhang
    Jie Xu
    Lu Xie
    Wei Guo
    Asian Pacific Journal of Tropical Medicine, 2022, 15 (06) : 266 - 273
  • [38] A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+AR+ metastatic or locally advanced breast cancer
    Krop, I.
    Cortes, J.
    Miller, K.
    Huizing, M. T.
    Provencher, L.
    Gianni, L.
    Chan, S.
    Trudeau, M.
    Steinberg, J.
    Ugg, J. S.
    Liosatos, M.
    Paton, V. E.
    Peterson, A.
    Wardley, A.
    CANCER RESEARCH, 2017, 77
  • [39] Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol
    Chen, Maohui
    Huang, Yizhou
    Zhang, Shuliang
    Zeng, Taidui
    Huang, Guanglei
    Chen, Chun
    Zheng, Bin
    TRIALS, 2023, 24 (01)
  • [40] Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol
    Maohui Chen
    Yizhou Huang
    Shuliang Zhang
    Taidui Zeng
    Guanglei Huang
    Chun Chen
    Bin Zheng
    Trials, 24 (1)
12345